Publication | Closed Access

Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial

OncologyEsophageal CancerGastrointestinal OncologyPathologyImmune Checkpoint InhibitorCancer TreatmentPhase 1B–2MedicineRadiation OncologyHer2-positive Gastro-oesophageal Adenocarcinoma